Cambridge Cognition (COG), a company specialising in digital solutions for evaluating brain health, has secured a £2 million contract for a pivotal cancer therapy trial. Under the terms of the contract, the company will provide its exclusive cognitive assessments (CANTAB®) as an exploratory endpoint, with anticipated revenues to be recognised over the next five years.
Cognitive decline associated with cancer predominantly impacts attention, memory, and executive function. The CANTAB® assessment tool possesses the necessary sensitivity and specificity to measure these distinct cognitive processes. Recognising this, CANTAB® has been selected as an exploratory endpoint in this pivotal oncology trial.
Supported by the Company's experienced clinical project management team, CANTAB® will be deployed in 9 countries and in 11 languages to accurately assess cognition across 70 trial sites.
Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: "Advances in cancer treatment have led to increased consideration for limiting the side-effects that impact patients' quality of life. Reducing cognitive impairment could have a major impact on patients' lives. We are pleased to be working with a major pharmaceutical company to support their development programme. With significant investment being made in cancer trials by the world's leading pharmaceutical companies, we expect that this could become a considerable growth area for Cambridge Cognition in the future."
View from Vox
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
Over the past decade, regulatory approvals for oncology drugs have nearly tripled, from 16 approvals in 2013 to 43 approvals in 2022. This surge in approvals has prompted pharmaceutical companies to invest heavily in minimising long-term side effects, including cognitive impairment, which affects around 30% of patients after chemotherapy.
Within oncology, research is needed to establish a better understanding of cognitive changes and impairments associated with cancer so that optimal patient outcomes can be achieved, with Cambridge Cognition strategically well placed to assist.
Follow Cambridge Cognition for more News and Updates: